Schering-Plough Corporation Suspends One of Five Pharmacopeia Drug Discovery Partnered Clinical Development Programs

NEW YORK (AP) -- Drug developer Pharmacopeia Drug Discovery Inc. says Schering-Plough Corp. is suspending development of a clinical compound for a metabolic disease, according to a filing with the Securities and Exchange Commission.